Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsResearchers investigating receptors, unvalidated ligand‑receptor complexes and poorly defined signaling interfaces often encounter technical limitations with conventional peptide screening technologies, particularly regarding maintenance of conformational integrity and preservation of post‑translational modifications (PTMs). Creative Biolabs' proprietary yeast‑display‑enabled peptide discovery service directly overcomes these bottlenecks. Our integrated platform enables comprehensive ligand library screening for target receptors, systematic identification of core signaling interaction sites, and de‑novo discovery of peptide binders for uncharacterized receptors. Clients obtain rigorously validated hit compounds with robust binding profiles, applicable to subsequent functional validation, off‑target risk evaluation and lead candidate optimization.
Identify immunogenic peptide candidates for vaccine development or TCR‑directed therapeutics.
Improve affinity, stability, or selectivity of existing peptide leads through iterative mutagenesis and selection.
Assess how phosphorylation, glycosylation, or lipidation affects peptide‑receptor binding.
Combine machine‑learning library prediction with empirical yeast display screening for accelerated hit discovery.
For more information, please click Yeast Display Platform - Creative Biolabs
The pathway from target concept to validated peptide hit follows a structured, quality‑controlled sequence designed for reproducibility and transparency.
| Yeast display offers distinct advantages for peptide discovery that synthetic or bacterial systems cannot replicate. The eukaryotic secretory and folding machinery enables production of peptide libraries with native disulfide bridging, glycosylation patterns where relevant, and conformational integrity that mimics membrane‑associated presentation. Quantitative screening via FACS allows real‑time selection stringency adjustment, researchers can gate for high‑affinity binders, slow off‑rates, or cross‑reactive profiles in a single experiment. |
|
For detailed specifications on library diversity, vector systems, sorting parameters, and validation protocols, Yeast Display Platform - Creative Biolabs
Researchers investigating deorphanization projects or seeking to map previously unknown interaction interfaces receive not just hit sequences but contextual binding data that informs downstream validation strategy.
Peptides displayed on the yeast cell surface present in a native, unconstrained conformation that closely mimics interactions between membrane‑proximal ligands and their receptors. This design reduces false positives arising from misfolded or artificially immobilized peptides, delivering hit lists that translate more reliably to cellular contexts.
Unlike phage display, the yeast system supports proper formation of disulfide bonds, phosphorylation where engineered, and other eukaryotic post‑translational modifications critical for certain peptide‑receptor interactions.
High-speed sorting enables processing of libraries exceeding 108 unique clones with resolution down to 2‑fold affinity differences. Selection gates can be tuned incrementally across rounds to progressively tighten binding criteria.
Screens designed to assess cross‑reactivity across human, mouse, and non‑human primate orthologs are fully supported. This capability proves particularly valuable for off‑target analysis, species‑specific toxicology assessment, and identification of novel cytokine or growth factor receptor pairs where ligand specificity remains uncharacterized.
Explore our complete suite of yeast display technology offerings
Custom library design and construction covering diverse peptide scaffolds and diversities.
High‑throughput FACS‑based screening against soluble, membrane‑bound, or complex antigen targets.
Rationally improve antibody lead affinity and biophysical properties.
Enhance TCR specificity, affinity, or stability for cell therapy applications.
Full human antibody discovery from naïve or immune yeast display libraries.
End‑to‑end antibody hit generation against challenging targets.
Improve expression, stability, or activity of protein leads through directed evolution.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
